Welcome to STAT’s Biotech Q1 Scorecard, our emoji-enabled means of tracking 11 make-or-break events expected over the next three months. When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate sunglassed smiley, rocket ship, or, if merited, smiling pile of excrement. Read on for brief explanations of what we’re watching for from each company.
(If you’re wondering why Axovant Sciences (AXON) and AveXis (AVXS) are missing, it’s because they got ahead of the rest of the pack. For Axovant’s compound misfortune of trial failure and embarrassing correction, let’s go with this emoji; for AveXis’ situation with the FDA, we’ll do this one.)